Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-24

One of the good things about putting cells into a bandage that is being brought into proximity with an open wound is that they don't have to navigate to a particular site through the vasculature where their physical size could in itself be an impediment (they can get stuck in the finer capiliaries potentially and not get to where they are most needed) so exosomes being smaller might be a better solution delivering most of the therapeuitc payload - one caveat on that though - cell to cell contact also matters sometimes and an exosome may not be able to make cell to cell contact (and associated signalling) as its not a cell.

If CYP knew that it could produce cells that were equivalent to their 2D cells out of a 3D manufacturing model they be worth more now because they have a more scaled more read for commercialising manufacturing solution.

Currently though we don't know that we can produce cells that are as good from 3D as 2D. It is known that hanging drop 3D manufacturing methods (not with CYP MSCs but other MSCs) don't produce cells that produce the same set of cell products. Its not to my knowledge known if the 3D microcarrier approach (which is essentially making 2D surface adhering cells adhere to something like a table tennis ball with holes in it floating in a 3D volume - so its just increasing the surface area available in the same 3D solution - traditional 2D only uses the floor) will work.

IF CYP had a microcarrier 3D solution proven up - so we'd need a way to separate the cells from the microcarriers without harming the cells - we'd be a lot more valuable in my opinion at present.